Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Analyst Confidence Soars for Daqo New Energy Despite Quarterly Loss

Robert Sasse by Robert Sasse
September 11, 2025
in Analysis, Earnings, Renewable Energy, Semiconductors
0
Daqo New Energy Stock
0
SHARES
183
VIEWS
Share on FacebookShare on Twitter

In a solar sector grappling with severe oversupply and collapsing prices, one Chinese polysilicon producer is receiving a surprising vote of confidence from Wall Street. Citigroup issued a spectacularly bullish upgrade for Daqo New Energy Corp., dramatically raising its price target even as the company posted a multi-million dollar quarterly loss and negative margins. This divergence between current financial results and future optimism forms a compelling market narrative.

Citigroup’s Bullish Stance

In a powerful show of conviction, Citigroup analyst Air Ma boosted the firm’s price target for Daqo New Energy from $27 to $37 per share—a substantial 37 percent increase. The bank also reaffirmed its “Buy” rating on the equity. This aggressive move is particularly notable as it follows Citi’s initiation of coverage on the stock just weeks prior, signaling a deep and rapidly formed confidence in the company’s long-term trajectory, looking beyond present challenges.

Deciphering the Q2 Financial Results

The company’s operational performance for the second quarter, reported in August, presented a mixed but telling picture. While revenue of $75.2 million missed analyst expectations by a significant 42%, the adjusted loss per share of -$0.86 was less severe than the anticipated -$1.00. The extreme pressure on selling prices was starkly evident in a negative gross margin of 108%.

However, the true story of resilience is found on the balance sheet. Daqo New Energy holds a formidable war chest of over $2.6 billion in cash and cash equivalents, all while carrying zero debt. This immense financial flexibility provides a critical buffer to navigate the ongoing industry downturn from a position of exceptional strength.

Should investors sell immediately? Or is it worth buying Daqo New Energy?

A $100 Million Signal from Management

Backing their optimistic outlook with concrete action, Daqo’s management and board of directors authorized a new $100 million share repurchase program, effective through the end of 2026. The program, to be funded from existing cash reserves, serves as a powerful statement. It indicates that company leadership views its current valuation as fundamentally undervalued and is committed to directly enhancing shareholder value.

Sector Pressures and a Glimmer of Hope

The global polysilicon industry continues to be plagued by overwhelming overcapacity, yet Daqo projects a cautious recovery. The company provided a third-quarter production guidance of 27,000 to 30,000 metric tons, with full-year output expected to land between 110,000 and 130,000 metric tons. This tempered optimism is partly predicated on anticipated regulatory interventions from the Chinese government, which are expected to help rationalize production capacity across the sector.

The critical question remains whether Daqo New Energy can leverage its billion-dollar safety net and potential regulatory support to not only survive the current crisis but emerge as a more dominant player. For now, a major financial institution is betting that it can.

Ad

Daqo New Energy Stock: Buy or Sell?! New Daqo New Energy Analysis from February 7 delivers the answer:

The latest Daqo New Energy figures speak for themselves: Urgent action needed for Daqo New Energy investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Daqo New Energy: Buy or sell? Read more here...

Tags: Daqo New Energy
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
CrossFirst Bankshares Stock
Analysis

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Myers Industries Stock
Analysis

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
Next Post
Certara Stock

Can Certara's Market Leadership in Biosimulation Spark a Stock Revival?

Palantir Stock

Defense Contracts Propel Palantir's AI Ambitions to New Heights

Mack-Cali Realty Stock

Veris Residential's Strategic Shift Gains Momentum

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com